Given the clinical success of anti‐PD‐1/PD‐L1 immunotherapy, SHP2 inhibitors serve as small molecule tumor immunotherapeutic agents and are considered important complements to PD‐1/PD‐L1 inhibitors, holding great promise in clinical practice. This evidence concerns the gene PTPN11 and neoplasm.